Anticoagulant therapy plays a vital role in preventing and treating thromboembolic diseases, and the demand for safe, effective, and population-specific anticoagulants is increasingly prominent in clinical practice. As a low molecular weight heparin (LMWH) with well-established efficacy, Dalteparin Sodium has broken new ground in serving special groups such as pediatric patients and pregnant women, addressing unmet clinical needs with its unique pharmacological advantages. Unlike conventional anticoagulants, it balances strong antithrombotic effects with favorable safety profiles, making it a reliable choice in personalized anticoagulant strategies.
A major breakthrough in the clinical application of Dalteparin Sodium is its approval for pediatric patients over 1 month old to reduce the risk of symptomatic thromboembolism. Pediatric venous thromboembolism often secondary to cancer, congenital heart disease, trauma, or venous catheterization, and prior to this approval, there were no anticoagulants specifically licensed for this population. A clinical study involving 38 children with symptomatic deep vein thrombosis or pulmonary embolism demonstrated the efficacy of Dalteparin Sodium: after 3 months of treatment tailored by age and weight, 21 children achieved complete thrombus resolution, 7 showed partial remission, and no patient experienced disease progression. This landmark application not only fills the gap in pediatric anticoagulant therapy but also provides a reassuring treatment option for clinicians and parents.
In the field of obstetrics and gynecology, Dalteparin Sodium has also become a cornerstone of anticoagulant therapy for pregnant women with thrombophilia or venous thromboembolism. Guidelines from the American College of Chest Physicians (ACCP) recommend LMWHs as the preferred choice for preventing and treating venous thromboembolism during pregnancy, and Dalteparin Sodium stands out due to its inability to cross the placental barrier and lack of secretion in breast milk. This ensures safety for both the mother and fetus, with no reported cases of fetal malformation associated with its use. For pregnant women with antiphospholipid syndrome who have a history of recurrent miscarriages, combining preventive doses of Dalteparin Sodium with low-dose aspirin has been proven to significantly improve pregnancy success rates, offering new hope for couples struggling with infertility due to thrombotic factors.
The pharmacological superiority of Dalteparin Sodium further supports its clinical value across diverse populations. With an average molecular weight of 5000 Da and an anti-factor Xa/anti-factor IIa ratio of 2.4, it exhibits strong antithrombotic activity while minimizing bleeding risks—an advantage particularly critical for special groups with fragile physiological conditions. Compared to unfractionated heparin, Dalteparin Sodium boasts higher bioavailability (approximately 90% via subcutaneous injection), a longer half-life, and does not require routine monitoring of coagulation function, simplifying treatment procedures and enhancing patient compliance. These characteristics make it suitable for both short-term acute treatment and long-term preventive care.
At Jiulong, we recognize the pivotal role of Dalteparin Sodium in addressing the anticoagulant needs of special populations and are dedicated to providing high-quality pharmaceutical products and professional clinical support for global healthcare. Our Dalteparin Sodium products adhere to stringent international quality control standards, ensuring stability and reliability in every dose to support optimal clinical outcomes. Whether you are a clinician seeking tailored anticoagulant solutions for pediatric or pregnant patients, or a patient in need of reliable thromboembolism prevention, please do not hesitate to contact our team. We will work closely with you to leverage the clinical value of Dalteparin Sodium and safeguard the health of vulnerable populations.